Sáenz-Cuesta et al. showed an increase in levels of CD41+ platelet-derived EVs in patients with MS compared with HCs [21], and these EVs were increased in all clinical forms of MS [62]. This evidence concerns the gene ITGA2B and myeloid sarcoma.